Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Current Leases (2022 - 2025)

Oramed Pharmaceuticals' Current Leases history spans 4 years, with the latest figure at $285000.0 for Q4 2025.

  • For Q4 2025, Current Leases changed N/A year-over-year to $285000.0; the TTM value through Dec 2025 reached $285000.0, changed N/A, while the annual FY2025 figure was $285000.0, N/A changed from the prior year.
  • Current Leases reached $285000.0 in Q4 2025 per ORMP's latest filing, up from $271000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $285000.0 in Q4 2025 to a low of $181000.0 in Q1 2025.
  • Average Current Leases over 4 years is $245933.3, with a median of $247000.0 recorded in 2022.
  • The largest YoY upside for Current Leases was 11.52% in 2025 against a maximum downside of 28.74% in 2025.
  • A 4-year view of Current Leases shows it stood at $247000.0 in 2022, then rose by 8.1% to $267000.0 in 2023, then fell by 8.99% to $243000.0 in 2024, then grew by 17.28% to $285000.0 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Current Leases are $285000.0 (Q4 2025), $271000.0 (Q3 2025), and $264000.0 (Q2 2025).